...offering: 18.7 million Placement agent: Peel Hunt Investors: Calculus Capital; new investors; existing investors Note: Epistem...

...prior: 10.6 million Placement agent: Peel Hunt Investors: Calculus Capital; new investors; existing investors Note: Epistem...

...for the PoC-HCV consortium project to develop point-of-care diagnostics and predictive test for HCV infection. Epistem...
...hand-held Genedrive PCR technology, which has CE Mark approval and provides rapid genotype test results. Epistem...
...Biosurfit, Qlucore, INSERM and INSERM's seed investment arm, Inserm Transfert. Biosurfit S.A. , Lisbon, Portugal Epistem Holdings plc...

...value chemical manufacture through industrial biotechnology" competition. The companies could not be reached for details. Epistem...
...epithelial stem cells. ScandiDerma is developing new dermatological ingredients derived from bioprospecting of arctic species. Epistem Holdings plc...

...it received CE Mark approval for its Genedrive point-of-care molecular test to diagnose tuberculosis (TB). EpiStem...
...technology is applicable to a range of viral, bacterial, fungal and somatic mutation disease area. EpiStem Holdings plc...

...glioblastoma and other brain tumors. CR 3294, an iNOS and matrix metalloproteinase (MMP) co-inhibitor from EpiStem Holdings plc...

...The companies partnered to research pulmonary fibrosis biomarkers under a three-year deal. EpiStem will contribute its...
...technology, which measures drug-induced gene expression changes from small tissue samples. Details were not disclosed. EpiStem Holdings plc...

...EpiStem will be responsible for regulatory approval for the diagnostic to diagnose tuberculosis (TB) infection. EpiStem...
...Program (RNTCP) to identify TB infection at an early stage (see BioCentury, July 4, 2011). EpiStem Holdings plc...